Legal questions swirl around FDA’s new expedited drug program, including who should sign off
"The concept of doing a review in one to two months just does not have scientific precedent," said Dr. Aaron Kesselheim, a professor at Harvard Medical School. "FDA cannot do the same detailed review that it does of a regular application in one to two months, and it doesn't have the resources to do it."
Espace publicitaire · 300×250